BioSpace News Archive

Gracell Biotechnologies Inc. today announced that the management team will participate in and attend one-on-one meetings at two upcoming investor conferences.

Atara Biotherapeutics, Inc. today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a virtual fireside chat at the Evercore ISI 5th Annual HealthCONx Conference on Wednesday, November 30, 2022, at 2:15 p.m.

Gamida Cell Ltd. today announced that members of the management team will present at the following upcoming investor conferences.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on Thursday, December 1, 2022 at 2:15 p.m. E.T.

Sintalica Bioscience Corp. today announced that the Company has received, through the University of Messina (the “University”), the following authorizations from the Italian Ministry of Health pertaining to its drug development program.

Neogen Corporation (NASDAQ: NEOG) announced today that the Company will participate in the Piper Sandler 34th Annual Healthcare Conference in New York City on Wednesday, November 30, 2022.

A novel approach to the treatment of opioid use disorder called Dual-Brain Psychology (DBP) has received a Phase II grant for continued research after publication showing promising results in a Phase 1 trial of 40 participants with opioid use disorder over the course of 4 weeks with an average decrease in opioid cravings of 71%.

AnchorDx, a world-leading developer of cancer early detection solutions, announced the first patient enrollment for the UriFind® bladder cancer assay clinical trial in the U.S., an over 1,000-patient multi-center, prospective testing of the assay in the targeted patients.

Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report the successful completion of its Good Laboratory Practice (“GLP”) studies on the AccuVAC-PT007 vaccine candidate specifically designed to target cervical cancer.

The global vitamin deficiency treatment market size was valued at US$ 5.86 billion in 2021 and is projected to expand at a CAGR of 6.6% from 2022 to 2030.